-
1
-
2
-
3دورية أكاديمية
المؤلفون: Anna Sofie Buhl Rasmussen, Christen Lykkegaard Andersen, Allan Weimann, Tianwu Yang, Camille Tron, Virginie Gandemer, Kim Dalhoff, Cecilie Utke Rank, Kjeld Schmiegelow
مصطلحات موضوعية: Biochemistry, Cell Biology, Genetics, Pharmacology, Biotechnology, Cancer, Hematology, Infectious Diseases, Chemical Sciences not elsewhere classified, ABL-class leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, imatinib, Philadelphia chromosome-like, Philadelphia chromosome positive, therapeutic drug monitoring, tyrosine kinase inhibitors
الإتاحة: https://doi.org/10.6084/m9.figshare.25205548.v1Test
https://figshare.com/articles/journal_contribution/Therapeutic_drug_monitoring_of_imatinib_how_far_are_we_in_the_leukemia_setting_/25205548Test -
4دورية أكاديمية
المؤلفون: Anna Sofie Buhl Rasmussen, Christen Lykkegaard Andersen, Allan Weimann, Tianwu Yang, Camille Tron, Virginie Gandemer, Kim Dalhoff, Cecilie Utke Rank, Kjeld Schmiegelow
مصطلحات موضوعية: Biochemistry, Cell Biology, Genetics, Pharmacology, Biotechnology, Cancer, Hematology, Infectious Diseases, Chemical Sciences not elsewhere classified, ABL-class leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, imatinib, Philadelphia chromosome-like, Philadelphia chromosome positive, therapeutic drug monitoring, tyrosine kinase inhibitors
-
5دورية أكاديمية
المؤلفون: Collins, James B, Muluneh, Benyam, Profitt, Sarah
المصدر: Journal of Oncology Pharmacy Practice, 30(2)
مصطلحات موضوعية: CML, Chronic myeloid leukemia, real world, tyrosine kinase inhibitor, TKI
العلاقة: https://doi.org/10.17615/1e86-6t16Test; https://cdr.lib.unc.edu/downloads/th83m9134?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/th83m9134Test
الإتاحة: https://doi.org/10.17615/1e86-6t16Test
https://cdr.lib.unc.edu/downloads/th83m9134?file=thumbnailTest
https://cdr.lib.unc.edu/downloads/th83m9134Test -
6مؤتمر
المؤلفون: Bharathi M. Rajamani, Raveen Stephen Stallon Illangeswaran, Esther Sathya Bama Benjamin, Balaji Balakrishnan, Daniel Zechariah Paul Jebanesan, Saswati Das, Aswin Anand Pai, Rakhi Thalayattu Vidhyadharan, Ajith Mohan, Sreeja Karathedath, Aby Abraham, Vikram Mathews, Shaji R. Velayudhan, Poonkuzhali Balasubramanian
مصطلحات موضوعية: Pharmacology, Basic Pharmacology, Clinical Pharmacology and Therapeutics, Clinical Pharmacy and Pharmacy Practice, Pharmaceutical Sciences, Pharmacogenomics, Toxicology (incl. Clinical Toxicology), Pharmacology and Pharmaceutical Sciences not elsewhere classified, chronic myeloid leukemia (CML), imatinib, RXRA, RXRA ligands, resistance
الإتاحة: https://doi.org/10.3389/fphar.2023.1187066.s002Test
https://figshare.com/articles/presentation/Presentation1_Modulating_retinoid-X-receptor_alpha_RXRA_expression_sensitizes_chronic_myeloid_leukemia_cells_to_imatinib_in_vitro_and_reduces_disease_burden_in_vivo_PPTX/23265758Test -
7دورية أكاديمية
المؤلفون: Faisal Mehmood
مصطلحات موضوعية: Chronic Myeloid Leukemia, In-Silico Analysis, Cassia angustifolia, Senna Makki
العلاقة: https://zenodo.org/record/7567536Test; https://doi.org/10.5281/zenodo.7567536Test; oai:zenodo.org:7567536
الإتاحة: https://doi.org/10.5281/zenodo.7567536Test
https://doi.org/10.5281/zenodo.7567535Test
https://zenodo.org/record/7567536Test -
8دورية أكاديمية
المؤلفون: Laura Mazzera, Manuela Abeltino, Guerino Lombardi, Anna Maria Cantoni, Stefano Jottini, Attilio Corradi, Micaela Ricca, Elena Rossetti, Federico Armando, Angelo Peli, Anna Ferrari, Giovanni Martinelli, Maria Teresa Scupoli, Carlo Visco, Massimiliano Bonifacio, Alessia Ripamonti, Carlo Gambacorti-Passerini, Antonio Bonati, Roberto Perris, Paolo Lunghi
المساهمون: Mazzera, Laura, Abeltino, Manuela, Lombardi, Guerino, Cantoni, Anna Maria, Jottini, Stefano, Corradi, Attilio, Ricca, Micaela, Rossetti, Elena, Armando, Federico, Peli, Angelo, Ferrari, Anna, Martinelli, Giovanni, Teresa Scupoli, Maria, Visco, Carlo, Bonifacio, Massimiliano, Ripamonti, Alessia, Gambacorti-Passerini, Carlo, Bonati, Antonio, Perris, Roberto, Lunghi, Paolo
مصطلحات موضوعية: Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive variants of chronic myeloid leukemia. We provide mechanistic insights into a previously undisclosed MEK1/2/BCR::ABL1/BCR/ABL1-driven signaling loop that may determine the efficacy of arsenic trioxide (ATO) in TKI-resistant leukemic patients. We find that activated MEK1/2 assemble into a pentameric complex with BCR::ABL1, BCR and ABL1 to induce phosphorylation of BCR and BCR::ABL1 at Tyr360 and Tyr177, and ABL1, at Thr735 and Tyr412 residues thus provoking loss of BCR’s tumor-suppression functions, enhanced oncogenic activity of BCR::ABL1, cytoplasmic retention of ABL1 and consequently drug resistance. Coherently, pharmacological blockade of MEK1/2 induces dissociation of the pentameric MEK1/2/BCR::ABL1/BCR/ABL1 complex and causes a concurrent BCRY360/Y177, BCR::ABL1Y360/Y177 and cytoplasmic ABL1Y412/T735 dephosphorylation thereby provoking the rescue of the BCR’s anti-oncogenic activities, nuclear accumulation of ABL1 with tumor-suppressive functions and consequently, growth inhibition of the leukemic cells and an ATO sensitization via BCR-MYC and ABL1-p73 signaling axes activation. Additionally, the allosteric activation of nuclear ABL1 was consistently found to enhance the anti-leukemic effects of the MEK1/2 inhibitor Mirdametinib, which when combined with ATO, significantly prolonged the survival of mice bearing BCR::ABL1-T315I-induced leukemia. These findings highlight the therapeutic potential of MEK1/2-inhibitors/ATO combination for the treatment of TKI-resistant leukemia
العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001022147500002; numberofpages:15; journal:LEUKEMIA; https://hdl.handle.net/11381/2953092Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85163592595
-
9دورية أكاديمية
المؤلفون: Hyunkyung Park, Hyeong-Joon Kim, Sang-Kyun Sohn, Yoonsuk Baik, Dongho Kim, Sung-Yeoun Lee, Jee Hyun Kong, Hawk Kim, Dong-Yeop Shin, Jae-Sook Ahn, Jinny Park, Seonyang Park, Inho Kim
مصطلحات موضوعية: Cardiology, Oncology and Carcinogenesis not elsewhere classified, Pharmacology and Pharmaceutical Sciences not elsewhere classified, chronic myeloid leukemia, droplet digital polymerase chain reaction, transcript type, treatment-free remission, tyrosine kinase inhibitor
الإتاحة: https://doi.org/10.25384/sage.24492825.v1Test
https://figshare.com/articles/journal_contribution/sj-docx-1-tah-10_1177_20406207231205637_Supplemental_material_for_Effect_of_BCR_ABL1_transcript_type_and_droplet_digital_polymerase_chain_reaction_on_successful_treatment-free_remission_in_chronic_myeloid_leukemia_patients_who_discontinued_/24492825Test -
10دورية أكاديمية
المؤلفون: Rodriguez, Jonathan, Iniguez, Abdon, Jena, Nilamani, Tata, Prasanthi, Liu, Zhong-Ying, Lander, Arthur D, Lowengrub, John, Van Etten, Richard A
مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Stem Cell Research - Nonembryonic - Non-Human, Orphan Drug, Stem Cell Research - Nonembryonic - Human, Cancer, Stem Cell Research, Hematology, Clinical Research, Mice, Animals, Tyrosine Kinase Inhibitors, Protein Kinase Inhibitors, Drug Resistance, Neoplasm, Myelopoiesis, Fusion Proteins, bcr-abl, Transgenic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, cancer biology, chronic myeloid leukemia, computational biology, hematopoiesis, mathematical model, mouse
وصف الملف: application/pdf
العلاقة: qt8d80k93t; https://escholarship.org/uc/item/8d80k93tTest
